Paolo Strati, MD

Trial finds CAR‑T approach shows minimal CRS and no neurotoxicity or prolonged cytopenia, enabling safer treatment for older, frail patients.

Macrophage cell therapy may skip lymphodepleting chemo, reducing toxicity and secondary cancer risk for heavily pretreated, frail patients.

RB-1355 reprograms autologous macrophages to heat up lymphoma tumors, avoid lymphodepletion, and deliver fast 1-week cellular therapy.

Although chemotherapy has represented the standard therapeutic modality for indolent non-Hodgkin lymphoma, monoclonal antibodies, immunomodulatory agents, targeted agents, bispecific antibodies, and cellular therapies are now available.